Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

25 Nov 2018

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms.

Recipharm's proprietary molecule Erdosteine has been officially recognised by the GOLD (Global Initiative for Chronic Obstructive Lung disease) Scientific Committee as one of the commonly used maintenance medications in COPD (Chronic Obstructive Pulmonary Disease).

Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

Erdosteine, which was discovered and developed in Italy by Recipharm’s facility in Paderno Dugnano, has been listed in the 2019 GOLD report. Since its introduction in 2001, the GOLD report has become a leading worldwide reference for all healthcare professionals and health authorities for the effective diagnosis, management and prevention of COPD.

Products containing Erdosteine from Recipharm are now marketed in over 40 countries across the world and is available in four different dosage forms including a capsule, sachet, dispersible tablet and suspension. Recipharm supplies Erdosteine as both API and as finished dose form to its customers.

Pierfrancesco Manzo, Sales & Business Development Director for Erdosteine commented: “This is an important recognition of the scientific value of our molecule and it has been achieved thanks to the outcomes of the recent clinical studies which proved Erdosteine to be effective in the treatment of COPD patients. We are confident that Erdosteine is going to play an increasing role in the treatment of this pathology.”

The recognition in the GOLD report follows extensive research as part of the RESTORE study published in 2017, which saw 467 patients in ten countries undergo 12 months of treatment with positive results that support its clinical effectiveness.

Erdosteine’s pharmacological profile is characterised by unique multifactorial activity: muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant. The chemical synthesis of the API and the manufacture of capsules and dispersible tablets is performed in Recipharm’s Paderno Dugnano facility, located just outside of Milan.

Read More

Related tags

Market News

Related news

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

18 Jul 2019

Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

Read more 
Combination technique improves polysaccharide characterization

Combination technique improves polysaccharide characterization

17 Jul 2019

The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

Read more 
Lubrizol integrates personal, home and health care divisions

Lubrizol integrates personal, home and health care divisions

16 Jul 2019

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

Read more 
Bosch finds buyers for its packaging machinery business

Bosch finds buyers for its packaging machinery business

16 Jul 2019

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

Read more 
New state-of-the-art cleanroom boosts production of anticancer drugs

New state-of-the-art cleanroom boosts production of anticancer drugs

15 Jul 2019

The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

Read more 
Colorcon chooses the Netherlands for new starch manufacturing plant

Colorcon chooses the Netherlands for new starch manufacturing plant

12 Jul 2019

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Read more 
GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more